Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment

Abstract Background Recently approved second‐generation androgen receptor inhibitors (SGARIs) for non‐metastatic castration‐resistant prostate cancer (nmCRPC) have similar efficacy but differ in safety profiles. We used a discrete choice experiment (DCE) to examine how nmCRPC patients and caregivers...

Full description

Bibliographic Details
Main Authors: Sandy Srinivas, Ateesha F. Mohamed, Sreevalsa Appukkuttan, Marc Botteman, Xinyi Ng, Namita Joshi, Jui‐Hua Tsai, Jarjieh Fang, A. Reginald Waldeck, Stacey J. Simmons
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Cancer Medicine
Subjects:
Caregivers
Choice Behavior
Patients
Prostatic Neoplasms, Castration‐Resistant
Risk Assessment
Online Access:https://doi.org/10.1002/cam4.3321

Internet

https://doi.org/10.1002/cam4.3321

Similar Items